Polysomy and amplification of chromosome 7 defined for EGFR gene in squamous cell carcinoma of the lung together with exons 19 and 21 wild type

被引:0
作者
Couceiro, Patricia [1 ,3 ]
Sousa, Vitor [1 ,2 ,3 ,4 ,5 ]
Alarcao, Ana [1 ,3 ]
Silva, Maria [1 ,3 ,4 ,5 ]
Carvalho, Lina [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Coimbra, Fac Med, Inst Patol, P-3000054 Coimbra, Portugal
[2] Hosp Univ Coimbra, Serv Patol, Coimbra, Portugal
[3] CIMAGO, Coimbra, Portugal
[4] Hosp Univ Coimbra, Serv Pneumol, Coimbra, Portugal
[5] Coimbra Univ Hosp, Ctr Pneumol, Coimbra, Portugal
关键词
Lung cancer; epidermoid carcinoma; paraffin-embedded tissue; EGFR; gene amplification; gene polysomy; GROWTH-FACTOR RECEPTOR; COPY NUMBER; CANCER; MUTATIONS; CHEMOTHERAPY; GEFITINIB;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small-cell lung cancers (NSCLC) and is a major target specific EGFR tyrosine kinase inhibitors (TKIs) developed and used for the treatment of advanced NSCLC. A number of biological factors are also associated with EGFR-TKIs responsiveness. This study was focused on EGFR somatic mutations and amplifications in squamous cell lung cancer. Material and methods: Representative sections of squamous cell carcinoma were selected from 54 surgical specimens from formalin-fixed paraffin-embedded tissues and submitted to TMA construction. Determination of EGFR protein expression was done by immunohistochemistry(IHC) (Zymed, Laboratories). Fluorescence in situ hybridization (FISH) was performed with LSI EGFR/CEP 7 (Vysis; Abbott Molecular, USA). Genomic DNA was extracted from 48 cases and exon 19 was amplified by polymerase chain reaction (PCR) for search deletions and point mutations for exon 21. All cases expressed high weigh cytokeratin and were observed negativity for CK7, CD56 and chromogranin. Results: EGFR protein overexpression was identified in 49 cases, by the application of Hirsh's scoring system. The chromosome 7 and EGFR gene were analyzed by FISH and scored according to Cappuzzo's method that showed high polysomy in 31 cases and amplification in 7 cases. Deletion in exon 19 of EGFR was detected in 3 cases of 48 samples; the exon 21 of EGFR was expressed in its wild type by RFLP in all cases. Conclusions: Detection of common EGFR deletion and mutation showed to be a rare event in Squamous cell carcinoma of the lung. While EGFR mutation is the most effective molecular predictor or sensitivity in patients with advanced NSCLC submitted to EGFR-TKIs treatment, amplification and polysomy is the most effective molecular predictor for EGFR-TKIs responsiveness in squamous cell carcinoma, when validated isolated from the group of NSCLC.
引用
收藏
页码:453 / 462
页数:10
相关论文
共 15 条
  • [1] EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Cappuzzo, Federico
    Ligorio, Claudio
    Toschi, Luca
    Rossi, Elisa
    Trisolini, Rocco
    Paioli, Daniela
    Magrini, Elisabetta
    Finocchiaro, Giovanna
    Bartolini, Stefania
    Cancellieri, Alessandra
    Hirsch, Fred R.
    Crino, Lucio
    Varella-Garcia, Marileila
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) : 423 - 429
  • [2] Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
    Hirsch, F. R.
    Varella-Garcia, M.
    Cappuzzo, F.
    McCoy, J.
    Bemis, L.
    Xavier, A. C.
    Dziadziuszko, R.
    Gumerlock, P.
    Chansky, K.
    West, H.
    Gazdar, A. F.
    Crino, L.
    Gandara, D. R.
    Franklin, W. A.
    Bunn, P. A., Jr.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (04) : 752 - 760
  • [3] The ErbB receptors and their role in cancer progression
    Holbro, T
    Civenni, G
    Hynes, NE
    [J]. EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) : 99 - 110
  • [4] The ErbB receptor tyrosine family as signal integrators
    Hynes, NE
    Horsch, K
    Olayioye, MA
    Badache, A
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (03) : 151 - 159
  • [5] Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    Inoue, Akira
    Suzuki, Takuji
    Fukuhara, Tatsuro
    Maemondo, Makoto
    Kimura, Yuichiro
    Morikawa, Naoto
    Watanabe, Hiroshi
    Saijo, Yasuo
    Nukiwa, Toshihiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) : 3340 - 3346
  • [6] Riely G.J., 2006, CLIN CANC RES, V12
  • [7] Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Okuda, Katsuhiro
    Kawano, Osamu
    Kitahara, Naoto
    Tanaka, Hisaichi
    Matsumura, Akihide
    Iuchi, Keiji
    Takada, Minoru
    Kawahara, Masaaki
    Kawaguchi, Tomoya
    Yukiue, Haruhiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (05) : 569 - 577
  • [8] Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585
  • [9] Shepherd FA, 2007, J CLIN ONCOL, V25
  • [10] Sunaga N, PHASE 2 PROSPECTIVE